Clinical Trials | July 18, 2023
PredOmix, Core Diagnostics partner to launch OncoVeryx-F
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
Revolutionary ovarian cancer rapid test available Q4 2022
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Subscribe To Our Newsletter & Stay Updated
